Those working in health, government and civil society to tackle antibiotic resistance should “strike while the iron’s hot” to apply and improve upon the lessons learnt during the Covid-19 pandemic, argued a panel of health experts during a webinar on 4 March 2021 organised by the Global Antibiotic Resistance and Development Partnership.
They were discussing what can be learnt from the Covid-19 pandemic and applied to tackling the “silent pandemic” of antibiotic resistance. All agreed that it is as urgent an existential threat as the Covid-19 pandemic.
About 700,000 people die of a drug-resistant infection each year. Bacteria can become resistant to antibiotics, which are designed to kill or slow their growth. These are microscopic, single-celled organisms.
South Africa has one of the highest rates of sexually transmitted infections (STIs) in the world, including for gonorrhoea. It is estimated that every year around two million people in the country get infected with the gonorrhoeae bacterium, which is likely to be an underestimate because most women don’t show any symptoms, according to a study published in the journal
PLOS ONE in 2018.
The World Health Organisation (WHO) estimates that, globally, there are 87 million cases of gonorrhoea annually, with the African region having the highest burden.
“If you look at the global number, South Africa represents about 2% of the cases which is quite high and could be an underestimate for a number of reasons including under-reporting and that women especially don’t show symptoms,” says Edward Mukwaya, who is the local clinical trial manager for a new antibiotic study being run, and fully funded by, the Global Antibiotic Research and Development Partnership (GARDP).
South Africa has one of the highest rates of sexually transmitted infections (STIs) in the world, including for gonorrhoea. It is estimated that every year around two million people in the country get infected with the gonorrhoea bacterium, which is likely to be an underestimate because most women don’t show any symptoms, according to a study published in the journal
PLOS ONE in 2018.
The World Health Organization (WHO) estimates that, globally, there are 87 million cases of gonorrhoea annually, with the African region having the highest burden.
“If you look at the global number, South Africa represents about 2% of the cases which is quite high and could be an underestimate for a number of reasons including under reporting and that women especially don’t show symptoms,” says Edward Mukwaya, who is the local clinical trial manager for a new antibiotic study being run, and fully funded by, the Global Antibiotic Research and Development Partnership (GARDP).
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global cephalosporin market reached a value of US$ 17.46 Billion in 2020. Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum.
These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infecti
GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea
The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea.
From:
12 February 2021
This investment, on top of £3.5 million committed in 2019, will support the Global Antibiotic Research and Development Partnership (
GARDP) in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
This new antibiotic has the potential to treat drug resistant gonorrhoea and is one of the few antibiotics in development specifically for the disease, an important consideration to ensure the treatment remains effective for generations to come.